Concise review - Treatment of multiple myeloma in the very elderly : How do novel agents fit in?
Copyright © 2016 Elsevier Inc. All rights reserved..
In the last decades, treatment of multiple myeloma (MM) has greatly improved due to the introduction of novel agents, including proteasome inhibitors (PI) and immunomodulatory agents (IMiDs). Given their generalized use at diagnosis and at relapse and their proven benefit for the large cohort of MM patients, it is of pivotal importance to also critically evaluate any benefit of these agents in very elderly (>75years) and frail patients. This review gives an overview of the benefits and toxicities of the currently available treatments in very elderly MM patients with a focus on first-line treatment. In addition we discuss the role of geriatric assessment to optimize treatment efficacy in the more vulnerable cohort.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Journal of geriatric oncology - 7(2016), 5 vom: 15. Sept., Seite 383-9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kint, Nicolas [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.12.2017 Date Revised 12.09.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jgo.2016.08.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM263810372 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM263810372 | ||
| 003 | DE-627 | ||
| 005 | 20231224204717.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jgo.2016.08.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0879.xml |
| 035 | |a (DE-627)NLM263810372 | ||
| 035 | |a (NLM)27567255 | ||
| 035 | |a (PII)S1879-4068(16)30103-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kint, Nicolas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Concise review - Treatment of multiple myeloma in the very elderly |b How do novel agents fit in? |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.12.2017 | ||
| 500 | |a Date Revised 12.09.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2016 Elsevier Inc. All rights reserved. | ||
| 520 | |a In the last decades, treatment of multiple myeloma (MM) has greatly improved due to the introduction of novel agents, including proteasome inhibitors (PI) and immunomodulatory agents (IMiDs). Given their generalized use at diagnosis and at relapse and their proven benefit for the large cohort of MM patients, it is of pivotal importance to also critically evaluate any benefit of these agents in very elderly (>75years) and frail patients. This review gives an overview of the benefits and toxicities of the currently available treatments in very elderly MM patients with a focus on first-line treatment. In addition we discuss the role of geriatric assessment to optimize treatment efficacy in the more vulnerable cohort | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Elderly patients | |
| 650 | 4 | |a Geriatric assessment | |
| 650 | 4 | |a IMiDs | |
| 650 | 4 | |a Multiple myeloma | |
| 650 | 4 | |a Proteasome inhibitors | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Immunologic Factors |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a Thalidomide |2 NLM | |
| 650 | 7 | |a 4Z8R6ORS6L |2 NLM | |
| 650 | 7 | |a Bortezomib |2 NLM | |
| 650 | 7 | |a 69G8BD63PP |2 NLM | |
| 700 | 1 | |a Delforge, Michel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of geriatric oncology |d 2010 |g 7(2016), 5 vom: 15. Sept., Seite 383-9 |w (DE-627)NLM203939069 |x 1879-4076 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2016 |g number:5 |g day:15 |g month:09 |g pages:383-9 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jgo.2016.08.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2016 |e 5 |b 15 |c 09 |h 383-9 | ||